TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$125 Million

IVERIC bio, Inc.

Follow-on Offering

Lead Left Bookrunner, June 2020

IVERIC bio, Inc.

IVERIC bio, Inc. is a science-driven biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The Company is currently developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases. The Company’s lead product candidate, Zimura, is a C5 complement inhibitor for the treatment of Geographic Atrophy (GA) secondary to dry Age-Related Macular Degeneration (AMD) and Autosomal Recessive Stargardt Disease (STGD1).